Markers of pro-inflammatory and pro-thrombotic state in the diagnosis of metabolic syndrome.
The metabolic syndrome refers to the clustering of upper body obesity, atherogenic dyslipidemia, insulin resistance and elevated blood pressure. Both, obesity and metabolic syndrome, have the potential to influence on the incidence and severity of cardiovascular disease with serious implications for worldwide health care systems. Obesity plays a central role in the development of insulin resistance and dyslipidemia through the mediation of a pro-inflammatory and pro-thrombotic state. Adipose tissue has been shown to exert important endocrine and immune functions. Pathogenesis of obesity associated metabolic syndrome is mediated by disturbed production and release of biologically active molecules by fat cells and other cells infiltrating fat tissue. In obese subjects synthesis of several bioactive compounds--adipokines and cytokines/chemokines by adipose tissue cells is dysregulated. Those bioactive molecules participate in regulation of apetite and energy homeostasis, lipid metabolism (tumour necrosis factor alpha--TNF-alpha), insulin sensitivity (TNF-alpha, adiponectin, resistin, visfatin) immunity (monocyte chemoattractant protein-1--MCP-1, TNF-alpha, IL-6), angiogenesis, blood pressure and hemostasis (plasminogen activator inhibitor--PAI-1). The effects of major pro-/anti-inflammatory and pro-thrombotic adipokines on several physiological processes will be discussed in this review. Also, an evidence-based approach to the laboratory diagnosis and treatment of metabolic syndrome will be presented.
Odrowaz-Sypniewska
G
G
Department of Laboratory Medicine, Collegium Medicum, Nicolaus Copernicus University, Bydgoszcz, Poland. odes@cm.umk.pl
D052242:Adiponectin / Q000378:metabolism; D002318:Cardiovascular Diseases / Q000175:diagnosis; D011416:Complement Factor D / Q000378:metabolism; D006801:Humans; D007249:Inflammation / Q000175:diagnosis / Q000473:pathology*; D015850:Interleukin-6 / Q000378:metabolism; D020738:Leptin / Q000378:metabolism; D024821:Metabolic Syndrome / Q000175:diagnosis / Q000473:pathology*; D008954:Models, Biological; D054409:Nicotinamide Phosphoribosyltransferase / Q000378:metabolism; D009765:Obesity / Q000628:therapy*; D017395:Plasminogen Activator Inhibitor 1 / Q000378:metabolism; D052243:Resistin / Q000378:metabolism; D012306:Risk; D013927:Thrombosis / Q000175:diagnosis / Q000473:pathology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D052242:Adiponectin; D015850:Interleukin-6; D020738:Leptin; D017395:Plasminogen Activator Inhibitor 1; D052243:Resistin; D014409:Tumor Necrosis Factor-alpha; D054409:Nicotinamide Phosphoribosyltransferase; D011416:Complement Factor D